The mid-stage trial showed that Reverset was effective as an add-on medication in tandem with other treatments. At 16 weeks, patients treated with 200mg Reverset, alongside their standard HIV treatment, showed a 54% response rate, as compared to a 40% response rate for patients not receiving the drug.
The study was designed to assess the efficacy, safety and tolerability of Reverset over a six-month period, to determine the most appropriate dose of Reverset, and to identify patients for whom Reverset is likely to provide the greatest benefit.
Dr Calvin Cohen, research director for Harvard Vanguard Medical Associates stated, “The 200mg dose of Reverset demonstrated potent, clinically meaningful antiviral effects in highly treatment-experienced patients, including patients carrying many of the common resistant viruses that we as physicians struggle to combat… The fact that Reverset was generally well tolerated in these highly treatment-experienced patients at the 200 mg once-daily dose is equally important and warrants confidence in its potential therapeutic value.”